Subjective Reasons for Non-Reporting of Adverse Drug Reactions in a Sample of Physicians in Outpatient Care

Abstract

Introduction: Drug safety surveillance strongly depends on the spontaneous reporting of adverse drug reactions (ADRs). A major limiting factor of spontaneous reporting systems is underreporting (UR) which describes incorrectly low reporting rates of ADRs. Factors contributing to UR are numerous and feature country-dependent differences. Understanding causes of and factors associated with UR is necessary to facilitate targeted interventions to improve ADR reporting and pharmacovigilance.

Methods: A cross-sectional questionnaire-based telephone survey was performed among physicians in outpatient care in a federal state of Germany.

Results: From n=316 eligible physicians n=176 completed the questionnaire (response rate=55.7%). Most of the physicians (n=137/77.8%) stated that they report ADRs which they have observed to the competent authority rarely (n=59/33.5%), very rarely (n=59/33.5%) or never (n=19/10.8%); the majority (n=123/69.9%) had not reported any ADRs in 2014. Frequent subjective reasons for non-reporting of ADR were (specified response options): lack of time (n=52/29.5%), the subjective evaluation that the required process of reporting is complicated (n=47/26.7%) or requires too much time (n=25/14.2%) or the assessment that reporting of an ADR is needless (n=22/12.5%); within open answers the participants frequently stated that they do not report ADRs that are already known (n=72/40.9%) and they only report severe ADRs (n=46/26.1%).

Discussion: Our results suggest a need to inform physicians about pharmacovigilance and to modify the required procedure of ADR reporting or to offer other reporting options.

Key words

drug safety surveillance - pharmacovigilance - survey - underreporting

• References

• 1 Borg J, Aislaintner G, Pirozynski M et al. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf 2011; 34: 187-197
• 2 Hazell L, Shakir S. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-396
• 3 Pushkin R, Frasetto L, Tsourounis C et al. Improving the reporting of adverse drug reactions in the hospital setting. Postgrad Med 2010; 122: 154-164
• 4 Martin R, Kapoor K, Wilton L et al. Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study. BMJ 1998; 317: 119-120
• 5 Irujo M, Beitia G, Bes-Rastrollo M et al. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf 2007; 30: 1073-1082
• 6 Khan S, Goval C, Chandel N et al. Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study. J Nat Sci Biol Med 2013; 4: 191-196
• 7 Santosh K, Tragulpiankit P, Edwards I et al. Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal. Int J Risk Saf Med 2013; 25: 1-16
• 8 Pérez García M, Figueras A. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals. Pharmacoepidemiol Drug Saf 2011; 20: 1295-1302
• 9 Lopez-Gonzalez E, Herdeiro M, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009; 32: 19-31
• 10 Tandon V, Mahajan V, Khajuria V et al. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian J Pharmacol 2015; 47: 65-71
• 11 dos Santos Pernas S, Herdeiro M, Lopez-Gonzalez E et al. Attitudes of Portuguese health professionals towards adverse drug reaction reporting. Int J Clin Pharmacol 2012; 34: 693-698
• 12 Hasford J, Goettler M, Munter K et al. Physicians’ knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 945-950
• 13 Biagi C, Montanaro N, Buccellato E et al. Underreporting in pharmacovigilance: an intervention for Italians (Emilia-Romagna region). Eur J Clin Pharmacol 2013; 69: 237-244
• 14 Herdeiro M, Ribeiro-Vaz I, Ferreira M et al. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf 2012; 35: 655-665
• 15 Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro M et al. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf 2013; 36: 317-328
• 16 Pagotto C, Varallo F, Mastroianni P. Impact of educational interventions on adverse drug event reporting. Int J Technol Assess Health Care 2013; 29: 410-417
• 17 Orsini M, Orsini P, Thorn D et al. An ADR surveillance program: increasing quality, number of incidence reports. Formulary 1995; 30: 454-461
• 18 Scott H, Thacher-Renshaw A, Rosenbaum S et al. Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA 1990; 263: 1785-1788
• 19 Wiktorowicz M, Lexchin J, Moscou K. Pharmacovigilance in Europe and North America: divergent approaches. Soc Sci Med 2012; 75: 165-170
• 20 Kempf A, Remington P. New challenges for telephone survey research in the twenty-first century. Annu Rev Public Health 2007; 28: 113-126
• 21 Bundesministerium für Gesundheit. Daten des Gesundheitswesen. 2013
• 22 Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reactions monitoring–cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf 1997; 6 (Suppl. 03) S71-S77
• 23 Miguel A, Azevedo L, Araújo M et al. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2012; 21: 1139-1154
• 24 Fincham J. Pilot projects to stimulate adverse drug reaction reporting. J Clin Pharm Ther 1987; 12: 243-247
• 25 Robins A, Weir M, Biersteker E. Attitudes to adverse drug reactions and their reporting among medical practitioners. S Afr Med J 1987; 72: 131-134
• 26 Rogers A, Israel E, Smith C et al. Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med 1988; 148: 1596-1600
• 27 Bundesärztekammer. (Muster-) Berufsordnung für die in Deutschland tätigen Ärztinnen und Ärzte – MBO-Ä 1997 – in der Fassung des Beschlusses des 118. Deutschen Ärztetages 2015 in Frankfurt am Main. 2015